Infraredx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery disease, announced today that its TVC Imaging System™ for the true vessel characterization of coronary artery disease will be highlighted in 13 presentations during the annual Transcatheter Cardiovascular Therapeutics Meeting (TCT 2013). TCT 2013, the world's largest educational meeting specializing in interventional cardiovascular medicine, will be held October 27-November 1, 2013 at The Moscone Center in San Francisco.

Newly accredited St. Joseph's Hospital Health Center, Syracuse N.Y., is the first hospital in New York and the second in the United States to accomplish accreditation in all three cardiovascular quality disciplines with the Accreditation for Cardiovascular Excellence (ACE): Diagnostic Cath, PCI and Carotid Artery Stenting (CAS), and is only one of two hospitals in New York State to achieve ACE accreditation distinction.

Diamondback 360(R) Coronary Orbital Atherectomy System Approved to Treat Severely Calcified Coronary Lesions.

Frequency domain optical coherence tomography (FD-OCT) yielded accurate heart measurements and was more accurate than intravascular ultrasound (IVUS) in detecting certain stent abnormalities, according to a study published in the October issue of JACC: Cardiovascular Imaging.

Pie Medical Imaging BV (PMI) announced today that they have signed an agreement with the Cardiovascular Research Foundation (CRF) to begin a close collaboration. Under this agreement the CRF Clinical Trials Center will use PMI’s solutions in their Angiographic Core Laboratory for clinical research and multi-center trials. As part of the agreement, CRF will also support further development of PMI’s new state-of-the-art products for analysis and visualization of medical images. The CRF Clinical Trials Center (CTC) plans and executes clinical investigations from first-in-man studies to large, multicenter, international trials and provides expert, independent qualitative and quantitative analyses of clinical and imaging data.

AccessClosure, Inc., the market leader in extravascular closure devices, announced today an exclusive agreement with Ostial Corporation to distribute the Flash Ostial System Dual Balloon Angioplasty Catheter in the United States. The Flash Ostial System is designed to help overcome the challenges of aorto-ostial stenting and compliments the Mynx® Product Family of Vascular Closure Devices to expand AccessClosure’s portfolio.

Data from a study led by researchers at Saint Luke's Mid America Heart Institute<http://globalmessaging1.prnewswire.com/clickthrough/servlet/clickthrough?msg_id=7563978&adr_order=59&url=aHR0cDovL3d3dy5zYWludGx1a2VzaGVhbHRoc3lzdGVtLm9yZy9zZXJ2aWNlcy9oZWFydC1hbmQt%0AdmFzY3VsYXItY2FyZGlvdmFzY3VsYXItc2VydmljZXM%3D> showed marked, long-term improvement in health status in patients suffering from peripheral artery disease treated with the S.M.A.R.T. Nitinol Self-Expandable Stent. The study was sponsored by Cordis Corporation, (Fremont, Calif.), manufacturer of the S.M.A.R.T. Stent.

BIOTRONIK, a leading manufacturer of cardiovascular technology, announced today that it has completed patient enrollment in the iliac arm of its BIOFLEX-I trial. Under the supervision of national primary investigator Dr. Mark W. Burket, Chief of the Cardiovascular Division at the University of Toledo Medical Center in Toledo OH, the trial will evaluate the safety and effectiveness of the Astron and Pulsar-18 stents in the treatment of peripheral vascular disease with a view towards gaining FDA approval.